Who are Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): tolterodine , mirabegron, Mirabegron with vaginal estrogen cream, Solifenacin + Mirabegron.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/beta3-agonists-adrenergic-mirabegron-vibegron.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Beta3-Agonists, Adrenergic [Mirabegron/Vibegron] — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Beta3-Agonists, Adrenergic [Mirabegron/Vibegron] (Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Beta-3 adrenergic agonist. Area: Urology / Neurology.

marketed Beta-3 adrenergic agonist Beta-3 adrenergic receptor (ADRB3) Urology / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Beta3-Agonists, Adrenergic [Mirabegron/Vibegron] (Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]) — Women and Infants Hospital of Rhode Island. Beta-3 agonists activate beta-3 adrenergic receptors on the detrusor muscle of the bladder to increase muscle relaxation and increase bladder capacity.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Beta3-Agonists, Adrenergic [Mirabegron/Vibegron] TARGET	Beta3-Agonists, Adrenergic [Mirabegron/Vibegron]	Women and Infants Hospital of Rhode Island	marketed	Beta-3 adrenergic agonist	Beta-3 adrenergic receptor (ADRB3)
tolterodine , mirabegron	tolterodine , mirabegron	Far Eastern Memorial Hospital	marketed	Antimuscarinic and beta-3 adrenergic agonist combination	Muscarinic M3 receptor and beta-3 adrenergic receptor
Mirabegron with vaginal estrogen cream	Mirabegron with vaginal estrogen cream	Mackay Memorial Hospital	marketed	Beta-3 adrenergic agonist (mirabegron) + topical estrogen (vaginal cream)	Beta-3 adrenergic receptor (mirabegron); estrogen receptor alpha and beta (vaginal estrogen)
Solifenacin + Mirabegron	Solifenacin + Mirabegron	University of Aarhus	marketed	Antimuscarinic + Beta-3 adrenergic agonist combination	M3 muscarinic receptor (solifenacin) and beta-3 adrenergic receptor (mirabegron)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Beta-3 adrenergic agonist class)

Women and Infants Hospital of Rhode Island · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Beta3-Agonists, Adrenergic [Mirabegron/Vibegron] — Competitive Intelligence Brief. https://druglandscape.com/ci/beta3-agonists-adrenergic-mirabegron-vibegron. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab